Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24859364

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2014 Jul 24
First author
Branford S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2014 Jul 24;124(4):469-71. doi: 10.1182/blood-2014-06-578617.
    note
    Source null
    related pmid
    25061165
    relationship
    Comment in

Authors and identifiers

  1. name
    Branford S
    type
    Author
  2. name
    Yeung DT
    type
    Author
  3. name
    Parker WT
    type
    Author
  4. name
    Roberts ND
    type
    Author
  5. name
    Purins L
    type
    Author
  6. name
    Braley JA
    type
    Author
  7. name
    Altamura HK
    type
    Author
  8. name
    Yeoman AL
    type
    Author
  9. name
    Georgievski J
    type
    Author
  10. name
    Jamison BA
    type
    Author
  11. name
    Phillis S
    type
    Author
  12. name
    Donaldson Z
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Branford S
    type
    Author
  2. name
    Yeung DT
    type
    Author
  3. name
    Parker WT
    type
    Author
  4. name
    Roberts ND
    type
    Author
  5. name
    Purins L
    type
    Author
  6. name
    Braley JA
    type
    Author
  7. name
    Altamura HK
    type
    Author
  8. name
    Yeoman AL
    type
    Author
  9. name
    Georgievski J
    type
    Author
  10. name
    Jamison BA
    type
    Author
  11. name
    Phillis S
    type
    Author
  12. name
    Donaldson Z
    type
    Author
bibliography ids
  1. nci-bib-68779750033ab91557de4415
book metadata
content sha256
eecd9149599a3db5f911c718195f4c889e8c417bed53e370e690b5723c1bc764
document type
citation
dois
  1. 10.1182/blood-2014-03-566323
electronic publication date
display
2014 May 23
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24859364
immutable id
pubmed:24859364@eecd9149599a3db5f911c718195f4c889e8c417bed53e370e690b5723c1bc764
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
4
name
Blood
nlm unique id
7603509
pages
511-8
volume
124
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2014 Jul 24;124(4):469-71. doi: 10.1182/blood-2014-06-578617.
    note
    Source null
    related pmid
    25061165
    relationship
    Comment in
outcomes validated
false
pmid
24859364
provenance
batch id
063b6c38419f18d4021f
provider
NCBI PubMed ESummary
record sha256
e0fbc0cfe55dc37e52cb6ab28d48d1ac296070c1543e079c33f38acce938850c
response sha256
5abcae41e9384a85f92695ef76b244ffd933f07a58a51082c160af8743d196ad
retrieved at
2026-09-09T23:47:02.607425+00:00
publication date
display
2014 Jul 24
precision
day
year
2014
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24859364/
title
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Preserved source evidence · Not medical advice